Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Aspirin vs Rivaroxaban for VTE Prophylaxis

N Engl J Med; 2018 Feb 22; Anderson, et al

Among patients who received 5 days of rivaroxaban prophylaxis after total hip or total knee arthroplasty, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism (VTE), a recent study found. The double-blind, randomized, controlled trial included 3,424 patients; 1,804 were undergoing total hip arthroplasty and 1,620 undergoing total knee arthroplasty. All patients received once-daily oral rivaroxaban (10 mg) until postoperative day 5 and then were randomly assigned to continue rivaroxaban or switch to aspirin (81 mg daily) for an additional 9 days after total knee arthroplasty or for 30 days after total hip arthroplasty. Patients were followed up for 90 days. Researchers found:

  • VTE occurred in 11 of 1,707 patients in the aspirin group and in 12 of 1,707 patients in the rivaroxaban group.
  • Major bleeding complications occurred in 8 patients in the aspirin group and in 5 patients in the rivaroxaban group.
  • Clinically important bleeding occurred in 22 patients in the aspirin group and in 17 in the rivaroxaban group.

Citation:

Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018; 378:699-707. doi:10.1056/NEJMoa1712746.

This Week's Must Reads

Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al

Diabetes & Long-Term Kidney Disease, Diabetes Care; ePub 2018 Jun 1; Warren, et al

Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al

Efficacy of Brief Behavioral Treatment for Insomnia, Sleep Medicine; ePub 2018 Jun 2; McCrae, et al

Opioid-Related Adverse Events in Surgical Patients, JAMA Surg; ePub 2018 May 23; Shafi, et al

Must Reads in Cardiology

Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al

Aspirin Benefit in Adverse Pregnancy Outcomes, Hypertension; ePub 2018 May 25; Hauspurg, et al

Monitoring NT-proBNP in Patients with Diabetes, Diabetes Care; ePub 2018 May 30; Jarolim, et al

CV Health Scores & Increased Risk of CVD and Death, J Am Heart Assoc; ePub 2018 May 17; Enserro, et al

Plasma Methylglyoxal Levels & Diabetic CVD, Diabetes Care; ePub 2018 May 21; Hanssen, et al